CorMedix (NASDAQ:CRMD) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of CorMedix (NASDAQ:CRMD) in a report released on Wednesday,Benzinga reports. They currently have a $15.00 price objective on the stock.

A number of other brokerages have also recently weighed in on CRMD. StockNews.com upgraded shares of CorMedix to a “sell” rating in a research note on Friday, November 8th. Royal Bank of Canada upped their target price on shares of CorMedix from $11.00 to $12.00 and gave the company an “outperform” rating in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

CorMedix Trading Up 2.6 %

Shares of CorMedix stock opened at $10.11 on Wednesday. The firm has a fifty day simple moving average of $10.47 and a 200-day simple moving average of $9.44. CorMedix has a 1-year low of $3.03 and a 1-year high of $13.85. The stock has a market capitalization of $613.44 million, a price-to-earnings ratio of -12.48 and a beta of 1.57.

Hedge Funds Weigh In On CorMedix

Several large investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in CorMedix by 1.9% during the 4th quarter. Bank of America Corp DE now owns 60,115 shares of the company’s stock valued at $487,000 after purchasing an additional 1,124 shares during the last quarter. FMR LLC raised its stake in shares of CorMedix by 54.3% in the 3rd quarter. FMR LLC now owns 4,618 shares of the company’s stock valued at $37,000 after buying an additional 1,625 shares in the last quarter. Nuveen Asset Management LLC raised its stake in shares of CorMedix by 1.0% in the 4th quarter. Nuveen Asset Management LLC now owns 171,978 shares of the company’s stock valued at $1,393,000 after buying an additional 1,679 shares in the last quarter. AlphaMark Advisors LLC raised its stake in shares of CorMedix by 16.7% in the 4th quarter. AlphaMark Advisors LLC now owns 14,000 shares of the company’s stock valued at $113,000 after buying an additional 2,000 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of CorMedix by 2.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 149,834 shares of the company’s stock valued at $1,214,000 after buying an additional 3,221 shares in the last quarter. 34.18% of the stock is currently owned by institutional investors and hedge funds.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.